Canadian practice guideline does NOT recommend HIFU

High-intensity focused ultrasound (HIFU) is legally available in Canada as a method for the treatment of prostate cancer. However, a new Canadian practice guideline states that, “HIFU cannot currently be recommended as an alternative to accepted curative treatment approaches for localized prostate cancer.”

The new guidance document has been issued by the Genitourinary Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care, and the full text of the guideline is available on line.

The guidance is based on a review of 29 studies of HIFU (using both the Ablatherm and the Sonoblate devices) as primary therapy and a further five studies of HIFU when used as salvage therapy in men who had failed a prior treatment.

The guidance document includes the following additional statements:

  • “HIFU should be considered an investigational treatment, with its use restricted to clinical trials, and to patients for whom other local treatment options are not suitable.
  • “The results from case series of HIFU require confirmation in well-designed prospective studies of sufficient size with appropriate (and validated) end points before HIFU can be considered a standard treatment option.”
  • “The common complications (medians) associated with HIFU [when used as a first-line treatment] included impotence (44% among previously potent patients), urinary tract infections (7.5% of patients), urethral stricture (12.3%), stenosis (7.8%), urinary incontinence (8.1%), urinary retention (5.3%), chronic perineal pain (3.4%) and urethrorectal fistula (1.0%).”

The “New” Prostate Cancer InfoLink expects that this guidance document will be distressing to men whose clinical outcomes to date suggest that they have been treated successfully with HIFU. However, we also believe that the document reflects the failure of the developers of HIFU technology to adequately fund and ensure the completion and publication of well-designed studies designed to demonstrate the effectiveness and safety of HIFU as a treatment for localized prostate cancer.

As we have indicated previously, we are aware of only one large, published case series that clearly reports data on the use of HIFU in a manner sufficient for evaluation of this technique as a first-line treatment for localized prostate cancer.

2 Responses

  1. Clearly that study does not reflect well on the Canadian doctors. Choosing one’s doctor is of utmost importance. HIFU looks easy but it takes skill, ability to read the ultrasound, patience and experience.

    I wonder what the stats were on surgery when it was first started.

  2. Dear Ron:

    I think you are missing the point. This guideline is based on the global reported HIFU data and has nothing to do (specifically) with the Canadian doctors who have been using HIFU.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: